title: Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism.
abstract: BACKGROUND
  This study aimed to evaluate whether laparoscopic splenectomy (Lap-Sp) contributes to the completion and curability of combined peginterferon and ribavirin (peg-IFN + RIB) therapy for cirrhotic patients with pancytopenia due to hypersplenism.
  
  
  METHODS
  From December 2004 to September 2007, 21 patients underwent Lap-Sp before treatment with peg-IFN + RIB. All the patients were Child-Pugh class A or B with a mean platelet count of 5.7 x 10(4)/mm(3) and a mean leukocyte count of 2,830/mm(3). The hepatitis C virus (HCV) genotype was 1b for 18 patients and 2b for 3 patients. Of the 21 patients, 17 had a viral load exceeding 100 KIU/ml, and 4 had a load of less than 100 KIU/ml.
  
  
  RESULTS
  All the patients underwent Lap-Sp without severe complications. The average hospital stay was 12.7 days (range, 6-23 days). Platelet counts increased from a mean of 5.7 +/- 2.2 x 10(4)/mm(3) preoperatively to 19.6 +/- 7.6 x 10(4)/mm(3) postoperatively and remained above 7.0 x 10(4)/mm(3) during the subsequent peg-IFN + RIB therapy. The full course of therapy was completed for nine patients, with five obtaining a sustained virologic response and one obtaining a biologic response. The five patients who obtained a sustained virologic response had either HCV type 2b or 1b with a low viral load (<100 KIU). At this writing, treatment is ongoing for the remaining 12 patients.
  
  
  CONCLUSIONS
  Laparoscopic splenectomy allows patients with HCV cirrhosis and hypersplenism to receive full-dose peg-IFN + RIB therapy. Patients with HCV, genotype 2 or 1b and a low viral load, and hypersplenism may be good candidates for Lap-Sp.
authors.affiliation: Department of Surgery, Fukuoka City Hospital, 13-1 of Yoshizukahonmachi, Hakata-ku, Fukuoka 812-0046, Japan. a_tom411@yahoo.co.jp
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Akahoshi
authors.forename: Morimasa
authors.initials: M
authors.lastname: Tomikawa
authors.forename: Daisuke
authors.initials: D
authors.lastname: Korenaga
authors.forename: Koji
authors.initials: K
authors.lastname: Ikejiri
authors.forename: Motonori
authors.initials: M
authors.lastname: Saku
authors.forename: Kenji
authors.initials: K
authors.lastname: Takenaka
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006971:Hypersplenism / Q000209:etiology / Q000601:surgery*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D010535:Laparoscopy / Q000379:methods*; D007902:Length of Stay / Q000706:statistics & numerical data; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D013156:Splenectomy / Q000379:methods*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b
references.citation: Am J Surg. 1994 Jun;167(6):611-4
references.pmid: 8209939
references.citation: Hepatology. 2002 Nov;36(5):1273-9
references.pmid: 12395340
references.citation: Hepatology. 1999 Apr;29(4):1124-30
references.pmid: 10094956
references.citation: JAMA. 1991 Aug 14;266(6):849
references.pmid: 1865526
references.citation: Br J Surg. 2000 Mar;87(3):362-73
references.pmid: 10718950
references.citation: Ann Intern Med. 1999 Aug 3;131(3):174-81
references.pmid: 10428733
references.citation: J Gastroenterol. 2005 Nov;40(11):1076-7
references.pmid: 16322955
references.citation: Am J Surg. 2002 Dec;184(6):631-5; discussion 635-6
references.pmid: 12488196
references.citation: Hepatology. 1995 Dec;22(6):1682-8
references.pmid: 7489974
references.citation: Hepatology. 1998 Nov;28(5):1424-9
references.pmid: 9794931
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: Hepatogastroenterology. 2002 May-Jun;49(45):847-52
references.pmid: 12064005
references.citation: Semin Liver Dis. 1989 Nov;9(4):273-7
references.pmid: 2690351
references.citation: Ann Surg. 1982 Nov;196(5):518-24
references.pmid: 7125739
references.citation: Hepatology. 1993 Aug;18(2):309-14
references.pmid: 8340060
references.citation: J Gastrointest Surg. 2004 Jan;8(1):120-6
references.pmid: 14746844
references.citation: Gastroenterology. 2003 May;124(6):1711-9
references.pmid: 12761728
references.citation: Hepatology. 2007 Mar;45(3):579-87
references.pmid: 17326216
references.citation: Br J Radiol. 1981 Jun;54(642):492-5
references.pmid: 7237027
references.citation: World J Surg. 1998 Oct;22(10):1082-6
references.pmid: 9747171